Announcement on Obtaining Drug Registration Certificate for Dydrogesterone Tablets
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Obtaining Drug Registration Certificate for Dydrogesterone Tablets
Filed with SSE ·
On 6ix: 6ix.com/news/announcement-on-obtaining-drug-registration-certificate-for-dydrogesterone-tablets
6ix hasn’t read this filing yet.
Beijing Foyou Pharma Co., Ltd. on 6ix
Earlier from Beijing Foyou Pharma
- Announcement on Obtaining Drug Registration Certificate for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II)
- Announcement on Obtaining Drug Registration Certificate for Pioglitazone-Metformin Tablets (15 mg/850 mg)
- Announcement on Obtaining Drug Registration Certificate for Arotinolol Hydrochloride Tablets
- Announcement on Obtaining Drug Registration Certificate for Amlodipine Besilate and Benazepril Hydrochloride Capsules
- Announcement on Obtaining Drug Registration Certificate for Levothyroxine Sodium Tablets
Later from Beijing Foyou Pharma
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on Proposed Selection in the 11th National Centralized Drug Procurement
- Announcement on Obtainment of the Drug Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets (I)
- Announcement on the Election of Employee Directors and the Adjustment of Audit Committee Members
- Announcement on Approval Notice for Clinical Trials of Ketoprofen Gel Patch
Follow Beijing Foyou Pharma into a list and get an email when it puts out news.
Follow Beijing Foyou Pharma